Navigation Links
International Isotopes Inc. Announces 2010 Year End Financial Results
Date:4/4/2011

pense

($468,038)

($3,949)

$464,089

11,852%Net Loss

($6,802,014)

($4,580,925)

$2,221,089

48%Net (Loss) Per Common Share

($0.02)

($0.02)Weighted Ave. Sh. Outstanding

299,865,350

290,060,471About International Isotopes Inc.

International Isotopes Inc. manufactures a full range of nuclear medicine calibration and reference standards, high purity fluoride gases, and a variety of cobalt-60 products such as teletherapy sources.  The Company also provides a wide selection of radioisotopes and radiochemicals for medical devices, calibration, clinical research, life sciences, and industrial applications and provides a host of analytical, measurement, recycling, and processing services on a contract basis to clients

International Isotopes Inc. Safe Harbor Statement

Certain statements in this press release are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including the statements with respect to the Company's goals with respect to future trends in cobalt production, the availability of new shipping containers and growth in the transportation segment, economic impact to our business attributable to the economy, our plans for investments in facilities and infrastructure, our ability to launch new products, and enter into new agreements, forecasts of future revenues, rates of expenditure on the depleted uranium project, and the significance of the commercial opportunity that project provides to the Company.  Information contained in such forward-looking statements is based on current expectations and is subject to change.  These statements involve a number of risks, uncertainties and other factors that could cause actual results, performance or achievements of International Isotopes Inc. to be materially different from any future results, performan
'/>"/>

SOURCE International Isotopes Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
2. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
3. Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale dUrologie
4. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
5. International Expert Group Initiates Largest Multi-center Phase III Trial to Evaluate NeuroAid(TM) in Stroke Recovery
6. Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on SLx-4090 at The 16th International Symposium on Drugs Affecting Lipid Metabolism
7. Preclinical Data on Lead MEK Inhibitor, RDEA119, to be Presented at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
8. Tumor Growth Inhibition and Pharmacokinetic Profile of NKTR-102 (PEG-Irinotecan) in Multiple Solid Tumors To Be Presented at Upcoming AACR-NCI-EORTC International Conference
9. Preimplantation Genetic Diagnosis International Society Refutes American Society of Reproductive Medicine Opinion - States Preimplantation Genetic Screening is Beneficial When Performed in Experienced Centers
10. Survival Data for Avicenas Amyotrophic Lateral Sclerosis Drug Candidate, AL-02, to be Presented at 18th International Symposium on ALS/MND
11. CEL-SCI CEO to Present at the International Society for Pharmaceutical Engineering 2007 Chesapeake BioShowcase
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... 30, 2014 China Biologic Products, Inc. (NASDAQ: ... integrated plasma-based biopharmaceutical company in China ... third quarter 2014 financial results on Wednesday, November 5, ... Company,s management will hold a conference call at 7:30 ... is 8:30 p.m., Beijing Time on November 6, 2014, ...
(Date:10/30/2014)... , La fórmula de ... adquirir tolerancia a la proteína de leche de ... la leche de la vaca (APLV) es la principal alergia ... la APLV se trataba eliminando las proteínas lácteas ... es posible adquirir tolerancia oral en un número ...
(Date:10/30/2014)... YORK , Oct. 29, 2014 ... the basis of test type, technology, product, and ... register the highest growth rate in the newborn ... This high growth is attributed to various nations ... is a fundamental instrument used for expanded newborn ...
Breaking Medicine Technology:China Biologic to Report Third Quarter 2014 Financial Results 2Según expertos reunidos en el Simposio Allergy Day 2Según expertos reunidos en el Simposio Allergy Day 3NewBorn Screening Market by Test Type, Technology (Tandem Mass Spectrometry, Immunoassay, Enzyme Assay, Electrophoresis, Pulse Oximeter), Instrument, Accessories, Reagent & Assay Kit - Global Forecast to 2019 2NewBorn Screening Market by Test Type, Technology (Tandem Mass Spectrometry, Immunoassay, Enzyme Assay, Electrophoresis, Pulse Oximeter), Instrument, Accessories, Reagent & Assay Kit - Global Forecast to 2019 3
... 23, 2011 GeoVax Labs, Inc. (OTC Bulletin Board: ... of Phase 1 clinical trial testing of its HIV/AIDS vaccine ... of DNA and Recombinant Modified Vaccinia Ankara Vaccines Expressing HIV-1 ... The Journal of Infectious Diseases . A ...
... 23, 2011 Cardiogenesis Corporation (Pink Sheets: CGCP ... fourth quarter and full-year ended December 31, 2010 on Wednesday, ... its Executive Chairman, and William R. Abbott, its Senior Vice ... call that day at 5:00 p.m. Eastern time (2:00 p.m. ...
Cached Medicine Technology:GeoVax Announces Publication of Phase 1 Clinical Trial in The Journal of Infectious Diseases 2GeoVax Announces Publication of Phase 1 Clinical Trial in The Journal of Infectious Diseases 3GeoVax Announces Publication of Phase 1 Clinical Trial in The Journal of Infectious Diseases 4Cardiogenesis Corporation to Report 2010 Fourth Quarter and Full-Year Results on March 9th 2
(Date:10/30/2014)... Jacksonville, FL (PRWEB) October 30, 2014 ... non-profit offering therapeutic horseback riding to special needs individuals ... Annual Round-Up on Saturday, November 15 from 10-2:00 p.m. ... fun event is open to the public and is ... programs. , Admission to the HSS Round-Up is ...
(Date:10/30/2014)... California (PRWEB) October 30, 2014 REV'D ... bars are now available through a unique service called, ... site designed to empower the everyday athlete. The Feed ... best athletes and created a system to pass that ... to see REV’D® is now available on The Feed!” ...
(Date:10/30/2014)... October 30, 2014 Victory Healthcare, ... its 2014 third quarter infection rates and patient ... infection rates of only two percent or less, ... scores exceeding 98 percent. , “We are delighted ... included rising satisfaction scores,” said Robert Helms, chairman ...
(Date:10/30/2014)... News) -- Scientists who used stem cells to create ... could provide a new way to learn more about ... team used human pluripotent stem cells -- which can ... to grow the functional miniature stomachs, to study infection ... of ulcers and stomach cancer. The miniature stomachs ...
(Date:10/30/2014)... -- Many U.S. colleges have indoor tanning salons ... the risk for skin cancer, researchers report. ... women, so colleges should adopt tanning-free policies, to ... "Public health efforts are needed to raise university ... that indoor tanning poses to young adults in ...
Breaking Medicine News(10 mins):Health News:Horse Sense & Sensitivity, Jacksonville Non-profit, To Hold 2nd Annual Round-Up 2Health News:Nutrition Experts at TheFeed.com Get REV'D 2Health News:Nutrition Experts at TheFeed.com Get REV'D 3Health News:Victory Healthcare Releases Q3 Satisfaction, Infection Rates 2Health News:Victory Healthcare Releases Q3 Satisfaction, Infection Rates 3Health News:Many U.S. Colleges Have Indoor Tanning Salons On, Near Campus: Study 2
... University of Michigan Health System-led team of researchers has found ... the most serious complications in patients with leukemia, lymphoma and ... blood-forming cells. Known as a hematopoietic stem cell transplant, ... from a matched donor who is either a family member ...
... Research Hospital scientists advances a strategy for taming the ... and other medications that work by disrupting the activity ... small molecule developed at St. Jude. In this study, ... blocked the activity of genes in a cell signaling ...
... endoprosthetic joint replacement in patients with osteoarthritis. Henning ... current issue of Deutsches rzteblatt International ... cartilage defects often develop subsequent to injury or ... overview of currently available medical and surgical therapeutic ...
... Magnetic resonance imaging (MRI) is an established technique which over ... professionals to study biological phenomena in the body without using ... by normal MRI are, to put it simply, pictures of ... up of water. MRI produces images of the hydrogen nuclei ...
... HealthDay Reporter , THURSDAY, Oct. 20 (HealthDay ... have many more accidents than adults have zeroed in ... braking late, swerving abruptly and other common new-driver mistakes. ... likely and leave less time to react to hazards, ...
... of people who were suicidal has highlighted the main challenges they ... and decide what they should do about it. The ... College of Medicine and Dentistry, supported by Devon NHS Partnership Trust ... published in the British Medical Journal on 22nd October ...
Cached Medicine News:Health News:Biomarker detects graft-versus-host-disease in cancer patients after bone marrow transplant 2Health News:Research involving thyroid hormone lays foundation for more targeted drug development 2Health News:Research involving thyroid hormone lays foundation for more targeted drug development 3Health News:New instrument helps researchers see how diseases start and develop in minute detail 2Health News:Teen Drivers Prone to 'G-Force' Errors, Researchers Say 2Health News:Teen Drivers Prone to 'G-Force' Errors, Researchers Say 3Health News:Study highlights issues faced by friends and family of the suicidal 2
Straight shafts with polished finish. Teeth: 0.12 mm. Tying platform: 5.0 mm. Wide Serrated....
Angled 45 degree shafts with 1 x 2 teeth and 5 mm tying platform. Serrated handle with dull finish....
Straight shafts with 1 x 2 teeth and 6 mm tying platform. Wide serrated handle with polished finish....
Straight shafts with 1 x 2 teeth and serrated handle with polished finish....
Medicine Products: